What if aging didnโ€™t have to suck?โ€

Thatโ€™s the slogan of a new Harvard University spinout that plans to put millions behind a hotly disputed rejuvenation discovery.

The startup, Elevian, which is based in San Francisco, says it intends to explore whether daily injections of a protein called GDF11 can promote โ€œthe bodyโ€™s ability to restore itselfโ€ and eventually treat conditions including coronary artery disease, Alzheimerโ€™s, and the muscle-loss condition sarcopenia.